Delivery Order SPE2DB24D1201-SPE2DB25FJCXT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,648.59 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $11,573.95 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded without set-aside designation. AmerisourceBergen, a major...
- The Defense Logistics Agency awarded a delivery order valued at $18,133.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order fulfillment. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a $41,877.63 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens under a firm fixed price contract type. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this transaction. This delivery order constitutes a...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a $10,594.36 firm fixed price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 2, 2025. This non-set-aside award was issued on August 29, 2025, to support federal medical supply needs. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order valued at $4,165.68 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This competitive contract, executed on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $20,781.90 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of June 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $69,322.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 9, 2025. This competitive award, issued on September 8, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $5,482.95 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 11, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical supply chain, providing brand-name medications and medical devices to support military and...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJCXTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,153.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. The contract, issued on June 2, 2025, with completion targeted for June 3, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. This delivery order is a child contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling and extends through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this delivery order—is a major pharmaceutical distributor and critical federal medical procurement vendor. The company's extensive portfolio of federal contract awards through DLA encompasses diverse therapeutic categories including specialty medications, brand-name and generic drugs, vaccines, and medical devices. Repatha (evolocumab) is a PCSK9 inhibitor used for cardiovascular disease management, representing the type of specialty pharmaceutical commodities that support military and veteran healthcare systems. The DLA Troop Support is planning successor Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple anticipated awards across separate regions, positioning AmerisourceBergen to continue serving Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.2k | 6/2/25 |